Taken together, these data indicate that combined treatment with rapamycin and AICAR in a mouse preclinical model of RCC additively reduces signaling through the Akt/HIF‐2α/VEGF pathway, which plays a key role in tumor progression and metastasis. The gene discussed is VEGFA; the disease is renal cell adenocarcinoma.